CNTO 736

synthetic GLP-1 receptor agonist constructed from a GLP-1 peptide analog, a VH domain, and CH2 and CH3 domains of an Fc; affects insulin resistance and inhibits VLDL production

Also Known As:

CNTO-736; CNTO736

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - CNTO 736: 2

Experts

1.	Ort, Tatiana: 2 articles (01/2009 - 07/2008)
2.	Stojanovic-Susulic, Vedrana: 2 articles (01/2009 - 07/2008)
3.	Corssmit, Eleonora P M: 1 article (01/2009)
4.	Havekes, Louis M: 1 article (01/2009)
5.	O'Neil, Karyn: 1 article (01/2009)
6.	Parlevliet, Edwin T: 1 article (01/2009)
7.	Picha, Kristen: 1 article (01/2009)
8.	Pijl, Hanno: 1 article (01/2009)
9.	Romijn, Johannes A: 1 article (01/2009)
10.	Schröder-van der Elst, Janny P: 1 article (01/2009)

Related Diseases

1.	Insulin Resistance 01/01/2009 - "We evaluate the potential of acute and chronic CNTO736 treatment on insulin sensitivity and very low-density lipoprotein (VLDL) metabolism. " 01/01/2009 - "CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice."
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2009 - "The data suggest that CNTO736 may be a useful tool in the treatment of type 2 diabetes."
3.	Body Weight (Weight, Body) 07/01/2008 - "Diabetic rodents dosed chronically with CNTO736 have lower fasting and postprandial glucose and reduced body weight. "

Related Drugs and Biologics

1.	VLDL Lipoproteins
2.	Glucagon-Like Peptide-1 Receptor
3.	Glucose (Dextrose)